


Add-On Treatment with Pipamperon 8-12 (mean 9) mg (bid) after Treatment with Citalopram 10-20 (mean 30) mg (bid) during 20-60 (mean 33) days (PIPCIT ADD-ON) with HDRS-17 Totalscore = 29 at Baseline in MDD in comparison with the Standard Efficacy of Antidepressants in Clinical Trials*

HDRS-17 REDUCTION OVER 8 WEEKS IN MDD



A. KHAN et al, Symptom Reduction and Suicide Risk in Patients Treated With Placebo in Antidepressant Clinical Trials, ARCH. OF GENERAL PSYCHIATRY, VOL 57, APR 2000

BEST AVAILABLE COPY

Figure 1

HDRS-17 CHANGE FROM BASELINE: COMBO PIPAMPERON AS ADD-ON - CITALOPRAM vs SNRI (duloxetine) in MAJOR DEPRESSION




Figure 2

REMISSION RATES (HDRS-17 ≤ 7): COMBO PIPAMPERON AS ADD-ON - CITALOPRAM vs SNRI (venlafaxine) vs SSRI's vs PLACEBO in MAJOR DEPRESSION





Figure 3

Foregoing Treatment During 1-5 (mean 4) days with Pipamperon 8-12 (mean 10) g/day (bid) Followed With the Combination Treatment of Pipamperon and Citalopram 20-50 (mean 26) mg/day (bid) (PICIT FG 1-5) in MDD (HDRS-17 at BL = 23) in Comparison with the Standard Efficacy of Antidepressants in Clinical Trials*

HDRS-17 REDUCTION OVER 8 WEEKS IN MDD




A. KHAN et al, Symptom Reduction and Suicide Risk in Patients Treated With Placebo in Antidepressant Clinical Trials

Journal of Clinical Psychopharmacology, 2000; 20(1): 57-64

BEST AVAILABLE COPY

Figure 4

HDRS-17 CHANGE FROM BASELINE: COMBO PIPAMPERON- CITALOPRAM WITH A FORE-GOING TREATMENT OF 4 DAYS WITH PIPAMPERON 10mg/day vs SNRI (duloxetine) in MAJOR DEPRESSION



BEST AVAILABLE COPY

Figure 5

REMISSION RATES (HDRS-17 ≤ 7): COMBO PIPAMPERON-CITALOPRAM WITH A FORE-GOING TREATMENT OF 4 DAYS WITH PIPAMPERON 10mg/day vs SNRI (venlafaxine) in MAJOR DEPRESSION





Figure 6

Foregoing Treatment During 6-8 (mean 7) days with Pipamperon 8-12 (mean 11) mg/day (bid) Followed With the Combination Treatment of Pipamperon and Citalopram 20-40 (mean 30) mg/day (bid) (PPCIT FG 6-8) in MDD (HDRS-17 at BL = 28 in Comparison with the Standard Efficacy of Antidepressants in Clinical Trials*

HDRS-17 REDUCTION OVER 8 WEEKS IN MDD



A. KHAN et al, Symptom Reduction and Suicide Risk in Patients Treated With Placebo in Antidepressant Clinical Trials, ARCH. OF GENERAL PSYCHIATRY, VOL 57, APR 2000

BEST AVAILABLE COPY

Figure 7

HDRS-17 CHANGE FROM BASELINE: COMBO PIPAMPERON-CITALOPRAM WITH A FORE-GOING TREATMENT OF 7 DAYS WITH PIPAMPERON 11mg/day vs SNRI (duloxetine) in MAJOR DEPRESSION





Figure 8

Foregoing & Add-On Treatment with Pipamperon 8-12 mg/day (bid) and Citalopram 20-40 mg/day (bid) in MDD in Comparison with the Standard Efficacy of Antidepressants in Clinical Trials*

HDRS-17 REDUCTION OVER 8 WEEKS IN MDD



* A. KHAN et al, Symptom Reduction and Suicide Risk in Patients Treated With Placebo in Antidepressant Clinical Trials, ARCH. OF GENERAL PSYCHIATRY / VOL 57, APR 2000)

BEST AVAILABLE COPY

Figure 9

HDRS-17 CHANGE FROM BASELINE: Foregoing & Add-On Treatment with Pipamperon 8-12 mg/day (bid) and Citalopram 20-40 mg/day (bid) in comparison with the SNRI duloxetine in MAJOR DEPRESSION




Figure 10

REMISSION RATES (HDRS-17 ≤ 7): Foregoing & Add-On Treatment with Pipamperon 8-12 mg/day (bid) and Citalopram 20-40 mg/day (bid) in comparison with the SNRI venlafaxine in MAJOR DEPRESSION





Figure 11

BEST AVAILABLE COPY

Y-BOCS TOTAL SCORE: Foregoing & Add-On Treatment with Pipamperon 8-16 mg/day (bid) and Citalopram 30-80 mg/day (bid) in comparison with the SSRI fluvoxamine in OCD




—○— COMBO PIPAMPERON-CITALOPRAM (n=7)

---○--- FLUVOXAMINE Controlled Release mean
271 mg/day (n=253) (Hollander E, Journal of
Clinical Psychiatry 64: 640-647, Jun 2003)

Figure 12

**Y-BOCS OBSESSION SCORE: Foregoing & Add-On Treatment
with Pipamperon 8-15 mg/day (bid) and Citalopram 30-80 mg/day
(bid) in comparison with the SSRI fluvoxamine in OCD**



—○— COMBO PIPAMPERON-CITALOPRAM (n=7)

- -○- FLUVOXAMINE Controlled Release mean
271 mg/day (n=253) (Hollander E, Journal of
Clinical Psychiatry 64: 640-647, Jun 2003)

Figure 13

**Y-BOCS COMPULSION SCORE: Foregoing & Add-On Treatment
with Pipamperon 8-15 mg/day (bid) and Citalopram 30-80 mg/day
(bid) in comparison with the SSRI fluvoxamine in OCD**





Figure 14

CGI-SEVERITY SCORE: Foregoing & Add-On Treatment with Pipamperon 8 mg/day (bid) and Citalopram 20-40 mg/day (bid) in comparison with the SSRI in Panic Disorder



○ Paroxetine in the treatment of panic disorder, Journal of Clinical Psychiatry 65: 405-413, No. 3, Mar 2004

× COMBO PIPAMPERON-CITALOPRAM (n=3)

* Sertraline in the treatment of panic disorder, Journal of Clinical Psychiatry 65: 405-413, No. 3, Mar 2004

Figure 15